FENC
Fennec Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
Fennec Pharmaceuticals (FENC) Company Profile
Fennec Pharmaceuticals Inc.
A company that developing Sodium Thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients
Chemical and pharmaceutical
--
09/13/2017
NASDAQ Stock Exchange
35
12-31
Common stock
PO Box 13628
68 TW Alexander Drive
Research Triangle Park
NC 27709
Develops cell and exosome-based therapeutics.
Fennec Pharmaceuticals Inc., was incorporated under the Canada Business Corporations Act in September 1996 and re-incorporated under the Business Corporations Act on August 25, 2011. The company is a commercial-stage specialty pharmaceutical company dedicated to the prevention of ototoxicity caused by cisplatin. Its product PEDMARK has been approved in the US and other markets to reduce the risk of hearing loss in pediatric patients with local solid tumors receiving cisplatin.
